Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced Friday that it has filed patent infringement lawsuits against Sandoz, Inc., Annora Pharma Private Limited, Zydus Lifesciences Global FZE, and Zenara ...

On November 19, Block Inc. held its first Investor Day in three years. Jack Dorsey, the company’s cofounder, chief executive, and “Block Head,” took to the stage and summarily posed what many ...

ORLANDO, Fla., Nov. 13, 2025 /PRNewswire/ -- Ingenus Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of Conjugated Estrogens Tablets, USP, ...

Gilead Sciences, Inc. (NASDAQ:GILD) on Monday entered into settlement agreements to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., generic manufacturers that filed ...

The Food and Drug Administration on Tuesday quietly approved a generic form of mifepristone, one of the two medications used in most U.S. abortions. That makes the drug, from the company Evita ...

The decision enraged opponents of abortion, who have been pressuring the Trump administration to restrict access to abortion medication. By Pam Belluck The Food and Drug Administration has approved a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. For the first time, a generic GLP-1 has been approved by ...

A U.S. federal judge rejected Novartis' efforts to block the launch of a generic version of Entresto, its blockbuster cardiovascular disease drug, per a FirstWord PHARMA report. The report noted that ...

A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart failure ...

July 11 (Reuters) - Novartis (NOVN.S), opens new tab cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto before its patent ...